In our patient, co-occurring KRAS, TP53, and APC mutations—a classic colorectal-like molecular signature—provided critical insight into tumor biology, shifting the focus from an ambiguous immunophenotype to defined molecular pathways. This evidence concerns the gene KRAS and neoplasm.